In squamous cell carcinoma cases angiogenesis inhibitors are contraindicated due to increased risk of bleeding, [16] thus we expect that the squamous cell lung cancer patients recorded as treated with immunotherapy would not have received anti-VEGF treatment. Here, VEGFA is linked to squamous cell carcinoma.